Related Experiment Video
Updated: Aug 5, 2026
Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Published on: December 16, 2022
In Vitro Antitumor Properties of Simvastatin-Loaded SBA-16 Mesoporous Nanoparticles Using Two- and Three-Dimensional
Akram J Kadhim1, Ibrahim Tawfiq2, Mohamed El-Tanani3
1Pharmacological and Diagnostic Research Center (PDRC), Faculty of Pharmacy, Al-Ahliyya Amman University, P.O. Box 183, Amman 19328, Jordan.
Abstract:
Background/objectives: Colorectal cancer (CRC) remains a cause of cancer-related mortality worldwide, with therapeutic progress hindered by poor tumor selectivity and acquired drug resistance. This study investigated the anticancer efficacy of simvastatin, administered as a free drug or encapsulated within mesoporous SBA-16 nanoparticles (NPs), against HT-29 colorectal cancer cells in two-dimensional monolayer and three-dimensional spheroid culture models. Methods: SBA-16 NPs achieved drug-loading efficiency of 73.83% and accelerated cumulative release of 91.93% within 30 min, compared to 35.24% for the free drug. Cell viability and proliferation were assessed via MTT and clonogenic assays, while interleukin-6 (IL-6) levels were measured by ELISA to evaluate anti-inflammatory activity. Results: Simvastatin-loaded SBA-16 NPs reduced the IC50 from 27.86 µg/mL to 4.43 µg/mL, representing a 6.29-fold enhancement in cytotoxic potency (p < 0.001), and significantly inhibited colony formation and suppressed IL-6 secretion, indicating modulation of inflammatory pathways implicated in tumor progression. In the 3D spheroid model, the nanoparticle formulation induced dose-dependent inhibition superior to the free drug. Conclusions: These findings demonstrate that SBA-16 nanocarriers substantially amplify simvastatin's anticancer efficacy through improved drug solubilisation and rapid release kinetics under sink conditions, with possible-but not directly proven-enhanced cellular interaction/internalisation and modulation of tumor-associated inflammatory signaling. Direct uptake, penetration, mechanistic cell-death, normal-cell selectivity, and in vivo studies are warranted to confirm clinical applicability.
Insights
Simvastatin encapsulated in SBA-16 nanoparticles significantly enhances its anticancer effect against colorectal cancer (CRC) cells. This novel drug delivery system improves simvastatin
Area of Science:
- Nanotechnology
- Pharmacology
- Oncology
Background:
- Colorectal cancer (CRC) poses a significant global health challenge, with treatment limited by poor drug selectivity and resistance.
- Simvastatin, a statin drug, has shown potential anticancer properties but faces challenges in delivery and efficacy.
- Developing advanced drug delivery systems is crucial to overcome therapeutic limitations in CRC treatment.
Purpose of the Study:
- To investigate the enhanced anticancer efficacy of simvastatin when encapsulated in mesoporous SBA-16 nanoparticles (NPs) against colorectal cancer cells.
- To compare the performance of simvastatin-loaded SBA-16 NPs with free simvastatin in both 2D and 3D cell culture models.
- To evaluate the anti-inflammatory effects of the simvastatin-loaded NPs by measuring interleukin-6 (IL-6) levels.
Main Methods:
- Simvastatin was loaded into mesoporous SBA-16 nanoparticles, achieving high drug-loading efficiency and rapid release kinetics.
- HT-29 colorectal cancer cells were cultured in 2D monolayer and 3D spheroid models.
- Cell viability, proliferation, and cytotoxicity were assessed using MTT and clonogenic assays.
- Interleukin-6 (IL-6) levels were quantified using ELISA to evaluate anti-inflammatory activity.
Main Results:
- Simvastatin-loaded SBA-16 NPs demonstrated a 6.29-fold increase in cytotoxic potency compared to free simvastatin, significantly reducing the IC50 value.
- The nanoparticle formulation effectively inhibited colony formation and suppressed IL-6 secretion, suggesting modulation of inflammatory pathways.
- In 3D spheroid models, the simvastatin-loaded NPs exhibited superior dose-dependent inhibition compared to the free drug.
Conclusions:
- Mesoporous SBA-16 nanocarriers substantially enhance simvastatin's anticancer efficacy against colorectal cancer cells.
- The improved efficacy is attributed to enhanced drug solubilization and rapid release kinetics, potentially aided by improved cellular uptake.
- Further in vivo studies are warranted to confirm the clinical applicability of this nanocarrier system for CRC treatment.
